Pliant Therapeutics (PLRX) Fundamental Analysis: Revenue, Earnings & Valuation

2.10 / 10

Underperform

The security demonstrates concerning fundamental health (2.1/10). Positive indicators: Interest coverage ratio (EBIT / Interest expense) (%) and Total operating revenue (YoY growth rate %), although drawbacks are visible in Asset-MV and Fixed assets turnover ratio. Analytical conclusion: guarded.

Analysis Checks(4/10)

ROA (%)

Value-48.01

Score1/3

Weight-7.64%

1M Return-0.21%

Total operating revenue (YoY growth rate %)

Value142.02

Score2/3

Weight5.27%

1M Return0.14%

PB-ROE

Value-0.73

Score1/3

Weight98.85%

1M Return2.47%

Income tax / Total profit (%)

Value19.90

Score0/3

Weight-72.95%

1M Return-2.14%

Fixed assets turnover ratio

Value8523.80

Score1/3

Weight-66.39%

1M Return-1.93%

Annualized net profit margin on total assets (%)

Value-48.01

Score1/3

Weight-7.64%

1M Return-0.21%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-41.40%

1M Return-1.16%

Operating revenue (YoY growth rate %)

Value185.62

Score2/3

Weight15.11%

1M Return0.40%

Cost of sales ratio (%)

Value71.87

Score2/3

Weight-46.34%

1M Return-1.34%

Asset-MV

Value-0.72

Score1/3

Weight223.12%

1M Return5.15%

Is PLRX undervalued or overvalued?

PLRX scores 2.10/10 on fundamentals and holds a Premium valuation at present. Backed by its -61.55% ROE, 0.00% net margin, -0.54 P/E ratio, 0.45 P/B ratio, and 29.97% earnings growth, these metrics solidify its Underperform investment rating.